Safety and efficacy of biologics in patients with Down syndrome and hidradenitis suppurativa: a retrospective cohort study

• DOI: 10.1093/ced/llaf090
• Publication Date: 2025-02-24T04:47:30Z
• Authors: Linnea L Westerkam; Karla Santiago-So...; Alexandra Charrow; John W Frew; Christopher J Sayed

Patients with Down syndrome have increased incidence of inflammatory conditions, including hidradenitis suppurativa, which may require biologic medications for optimal disease management. This retrospective cohort study evaluated 27 patients with Down syndrome and comorbid hidradenitis suppurativa and demonstrated that biologics are well tolerated and effective in this cohort.